-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis-         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design-         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026-         Webcast of Earnings Call Today, August 13th at 4:30 p.m. ETCUPERTINO, Calif., Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2024 and provid ...